Upfront surgery for advanced ovarian cancer failed to improve overall survival (OS) versus interval debulking but did improve ...

In addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...

Primary surgery for advanced ovarian cancer significantly improves progression-free survival but not overall survival ...

Ovarian cancer isn't silent - learn the early warning signs. Persistent bloating, pelvic pain, urinary symptoms revealed.

One woman's story of literal strength illustrates how ovarian cancer symptoms can be missed—and the lighthearted recovery ...

Adding relacorilant to nab-paclitaxel improved survival outcomes in patients with platinum-resistant ovarian cancer.

Michele Hoaglund, who bought the store about a decade ago from its founding owners, was diagnosed with ovarian cancer around ...

Brian Slomovitz, MD, of Mount Sinai Medical Center, compares relacorilant plus nab-paclitaxel with existing treatments for platinum-resistant ovarian cancer and highlights the ROSELLA trial’s global ...

Researchers compare relacorilant plus nab-paclitaxel with nab-paclitaxel monotherapy in patients with platinum-resistant ...

Around one in 10 women will develop ovarian cysts at some point during their lives, and while the prospect of a cyst growing ...

Relacorilant/nab-paclitaxel significantly improved PFS and OS vs nab-paclitaxel alone in platinum-resistant ovarian cancer.